Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

'Alternative Alternatives' investment funds up 0.42% in November (+2.75% in first 11 months of 2012)

Wednesday, January 02, 2013

Florian Guldner, Opalesque Research:

'Alternatives Alternatives' investment funds made profits in November, according to an estimation based on 674 single- and multi-manager funds currently listed in 25 categories in the Opalesque Solutions A SQUARE Fund Database (Source).

The Opalesque A SQUARE Index gained 0.42% in November and is up 2.75% in the first eleven months of 2011. Estimates for October and September were corrected to -1.11% and +0.62%, respectively. The A SQUARE Funds of Funds Index lost 0.6% and is down 1.01% through the month of November.

  • November's best performers were real estate funds (+2.26%), followed by volatility traders (+1.75%) and structured finance funds (+1.22%). Trade finance and insurance-linked securities funds delivered robust gains of 0.80% and 0.51% respectively.
  • Negative results were posted by commodity-focused strategies: Base & precious metal strategies lost 4.34% and energy funds were down 2.70%.
  • Year-to-date, the ranking is led by real estate (+17%), structured finance (+16%) and infrastructure funds (+10%).

A SQUARE database weighting by asset classes

Over the last 12 months, the A SQUARE Index had 6 negative and 6 positive months with a compounded gain of 1.86%. The A SQUARE Funds of Funds Index gained 1.02% in the same period.

......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its